SLC7A11/xCT Rekombinanter Antikörper
SLC7A11/xCT Rekombinant Antikörper für IF/ICC, FC (Intra), ELISA
Wirt / Isotyp
Kaninchen / IgG
Getestete Reaktivität
human und mehr (1)
Anwendung
WB, IF/ICC, FC (Intra), ELISA
Konjugation
Unkonjugiert
CloneNo.
230227C5
Kat-Nr. : 82115-2-RR
Synonyme
Geprüfte Anwendungen
| Erfolgreiche Detektion in IF/ICC | A549-Zellen |
| Erfolgreiche Detektion in FC (Intra) | A549-Zellen, HeLa-Zellen |
Empfohlene Verdünnung
| Anwendung | Verdünnung |
|---|---|
| Immunfluoreszenz (IF)/ICC | IF/ICC : 1:125-1:500 |
| Durchflusszytometrie (FC) (INTRA) | FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Veröffentlichte Anwendungen
| WB | See 2 publications below |
| IF | See 1 publications below |
Produktinformation
82115-2-RR bindet in WB, IF/ICC, FC (Intra), ELISA SLC7A11/xCT und zeigt Reaktivität mit human
| Getestete Reaktivität | human |
| In Publikationen genannte Reaktivität | human, Maus |
| Wirt / Isotyp | Kaninchen / IgG |
| Klonalität | Rekombinant |
| Typ | Antikörper |
| Immunogen | SLC7A11/xCT fusion protein Ag25431 |
| Vollständiger Name | solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 |
| Berechnetes Molekulargewicht | 55 kDa |
| GenBank-Zugangsnummer | BC012087 |
| Gene symbol | SLC7A11 |
| Gene ID (NCBI) | 23657 |
| Konjugation | Unkonjugiert |
| Form | Liquid |
| Reinigungsmethode | Protein-A-Reinigung |
| Lagerungspuffer | PBS with 0.02% sodium azide and 50% glycerol |
| Lagerungsbedingungen | Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA. |
Hintergrundinformationen
SLC7A11 (also known as xCT) is a membrane transporter involved in the uptake of cystine. It promotes glutathione synthesis through the uptake of cystine and the concomitant release of glutamate. This, in turn, protects cells from oxidative stress, maintains cellular redox balance, and prevents cell death induced by lipid peroxidation. SLC7A11 has been identified as a potential target for cancer therapeutics. It is overexpressed in multiple malignant tumors and is closely associated with the growth, prognosis, metastasis, and treatment response of various cancers including lung cancer.
Protokolle
| PRODUKTSPEZIFISCHE PROTOKOLLE | |
|---|---|
| IF protocol for SLC7A11/xCT antibody 82115-2-RR | Protokoll herunterladen |
| FC protocol for SLC7A11/xCT antibody 82115-2-RR | Download protocol |
| STANDARD-PROTOKOLLE | |
|---|---|
| Klicken Sie hier, um unsere Standardprotokolle anzuzeigen |
Publikationen
| Species | Application | Title |
|---|---|---|
Front Immunol A disulfidptosis-related lncRNA signature for analyzing tumor microenvironment and clinical prognosis in hepatocellular carcinoma | ||
Biofactors Induction of UBQLN1-mediated PGC1α stability by isoliensinine overcame hypoxia-induced resistance in liver cancer cells | ||
Ren Fail Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production |



